NABTC Promotes First Brain Tumor Awareness Week

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 11
Volume 6
Issue 11

NEW YORK-The North American Brain Tumor Coalition (NABTC) kicked off the first Brain Tumor Awareness Week, October 19 to 25, 1997. The national event is designed to educate the public about the impact of brain tumors, as well as highlight the need for increased research funding.

NEW YORK—The North American Brain Tumor Coalition (NABTC) kicked off the first Brain Tumor Awareness Week, October 19 to 25, 1997. The national event is designed to educate the public about the impact of brain tumors, as well as highlight the need for increased research funding.

Said Susan Weiner, PhD, chair of the NABTC, “Our goal is to draw greater attention to a debilitating and often fatal disease for which the causes are still uncertain.” Each year, she said, approximately 100,000 people in the United States will be diagnosed with a primary or metastatic brain tumor.

To raise awareness about the need for increased research funding on Capitol Hill, the NABTC scheduled a Congressional Luncheon to take place during Brain Tumor Awareness Week.

The NABTC is also issuing a Patient Resource Guide during Brain Tumor Awareness Week to help connect brain tumor patients and their families with the various support services, informational materials, and programs provided by the coalition’s eight member organizations. A free copy can be obtained by calling 1-800-753-5877.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
2 experts in this video
Related Content